Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and efficacy of CAP-232 in the treatment
of patients with previously treated (refractory) renal cell carcinoma